

June 09, 2026

To, National Stock Exchange of India Limited, "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai – 400 051	To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	Scrip Code: 532296
ISIN: INE935A01035	ISIN: INE935A01035
Our Reference No. 21/26-27	Our Reference No. 21/26-27

Dear Sir/ Madam,

Sub: Investor Day Presentation

Further to our communication dated May 29, 2026, attached is the copy of the presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2026 which is scheduled today in Mumbai.

Request you to kindly take the same on record.

Thanking You.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS - 28839

Encl: As above




Redefining the Future

**Building a Global Innovation-led
Pharmaceutical Company**

Investor Day 2026

Tuesday, 9 June 2026



Disclaimer



This document has been prepared by Glenmark Pharmaceuticals Limited and the information, statements and analysis made in this document describing the Company's or its affiliates' objectives, projections and estimates are forward looking statements. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects”, “aspirations”, “goals”, “aim”, “targets”, “promises” and similar expressions.

These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements, depending upon, without limitation:

- General economic and political conditions in our key markets, government policies and other incidental factors;
- Changes in the overall macro-economic parameters including changes in the currency and interest rates either in India and / or globally;
- Ability to successfully implement our strategic plan, including research and development efforts;
- Changes in laws and regulations that apply to the pharmaceutical industry and its suppliers and customers; and
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry

Actual outcomes may vary materially from those indicated in the applicable forward-looking statements, should one or more of such risks and uncertainties materialize. No representation or warranty, either expressed or implied, is provided in relation to this presentation. This presentation should not be regarded by recipients as a substitute for the exercise of their own judgment. The Company undertakes no obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise.

This presentation is property of Glenmark Pharmaceuticals Limited. Do not alter in any way or reproduce without permission.

Today's Agenda



Redefining the Future: Building the Next Glenmark

Glenn Saldanha

Chairman & Managing Director



Scaling Global Growth Engines

Marc T. Kikuchi

President & Business Head – North America



Winning in Three Global Therapy Areas

Nishan de Silva, M.D.

Global Strategy Advisor



Advancing Innovation in Next-gen Biologics

Lida Pacaud, M.D.

President & Chief Executive Officer



Creating Long-term Shareholder Value

Anurag Mantri

Executive Director & Global Chief Financial Officer



Q&A Session

Redefining the Future

Building the Next Glenmark

Glenn Saldanha

Chairman & Managing Director



Differentiated Global Platform for Long-term Value Creation



To emerge as a **Leading, Research-led, Global** pharmaceutical company



Large Scale

~US\$2bn

consolidated revenue¹

~17,000

global employee base²



Focused

>60%

revenue contribution from
Branded portfolio³

3

key therapeutic areas globally



Diversified

>80

countries with presence

11


manufacturing sites² globally
across dosage forms

1. As of FY26 consolidated revenue in ₹, converted at the average exchange rate in 12M FY26 of 1US\$ = ₹88.33

2. As of April 2026

3. As per FY27e consolidated revenue; "Branded" include all branded markets (India, Emerging Markets, parts of Europe) and all branded products sold globally

Proven Track Record of Driving Innovation for Over Two Decades



Astria Therapeutics was acquired by BioCryst Pharmaceuticals in October 2025

1. IGI active partnerships: ISB 880, ISB 830+ and ISB 2001

2. GPL active partnerships: QINHAYO™ (Envafolimab), WINLEVI® (Clascoterone), JABRYUS® (Abrocitinib), AKYNZEO® (Netupitant/Palamosetron), TEVIMBRA® (Tislelizumab-jsgr) & BRUKINSA® (Zanubrutinib), Trastuzumab Rezetecan, Aumolertinib

Glenmark Today: A Strong Foundation for Long-term Success



Robust Branded business in India & Emerging Markets



Substantial US generics business & a sizable presence in European markets



Leading generic R&D capabilities in Respiratory & Injectables



Exceptional Innovative portfolio & partnerships



IGI's world-class multispecific antibody platform technology



Strong financial profile & balance sheet with superior return on capital

Capital Allocation Strategy Aimed at Value-Chain Enhancement



Strategic Focus Areas



Base Business



Innovation / Specialty



IGI



Key Investment Decisions To Further Propel Growth

- **India & Emerging Markets:** Expand presence across branded products in key therapeutic areas
- **USA:** Strengthen existing Respiratory & Injectable platform
- **Europe:** Gain scale in core markets across generics, Respiratory & Specialty
- **Innovative Oncology:** Expand commercial build-out in India & Emerging Markets
- **Specialty Dermatology & Respiratory:** Enhance portfolio in Europe
- **Innovative Dermatology & Respiratory:** Evaluate in-licensing global opportunities of novel assets in development
- **BEAT[®] Platform:** Continue investments to discover novel multispecific antibodies in Oncology
- **Target 1 IND filing** every year starting FY27

Strategic Roadmap to Achieve Long-term Vision



2026-2030

- Achieve Therapy Area dominance in Dermatology, Respiratory and Oncology in India & Emerging Markets
- Scale up the generic business in the US through Respiratory & Injectable launches
- Gain scale in Europe across generics & Specialty products
- Target 3-4 multispecific antibodies in IGI to enter clinical development & close additional new partnerships of a similar magnitude to ISB 2001

2030 – 2035

Become a **Leading, Global, Innovation-driven** company

- Globally commercialize 1-2 multispecific innovative products from IGI's Oncology portfolio via Glenmark, IGI & its Partners
- Gain leadership position in Respiratory & Injectables in the US generics market
- Scale-up Glenmark's presence in Innovative Dermatology & Respiratory
- Champion Indian Pharma on the global stage as a leader in Innovation

Scaling Global Growth Engines

Marc T. Kikuchi


President & Business Head – North America




Well Diversified Business Through Global Commercial Footprint




Revenue Contribution¹




Emerging Markets



Europe



North America



Key Markets

Russia / CIS, LATAM, MEA, APAC

WEU, CEE

USA, Canada



Key Focus Areas²

Respiratory, Dermatology, Oncology

1. As per FY27e consolidated revenue, excluding the deferred out-licensing income recognition for ISB 2001


2. Apart from the three key therapeutic areas, there are additional focus areas for some regions: India (Cardiac, Diabetes); US, EU generic markets: Focus on therapeutic area-agnostic dosage forms, such as Oral Solids, Topicals, Respiratory Devices, Injectables

India: Market-beating Performance Through Strong Brand-building



Growth 1.5x above IPM over the last 3 years¹

% growth



Sharp focus on core therapeutic areas²

Overall IPM

FY22

15th

FY26

13th



As per growth rate³

5th

2nd



Dermatology

2nd

2nd



Respiratory

4th

3rd



Cardiac

8th

4th



Oncology⁵

10th

5th



Diabetes

16th

21st



Legacy of creating mega-brands⁴

11

brands with
>₹1,000mn

16

brands with
>₹500mn

11

brands in
IPM Top-300



Key differentiated launches

GLIPIQ

nebZmart-GFB

GLENMARK AIRZ-FB
Smartules


VILOR-FG

TEVIMBRA
(tisielizumab)

Brukinsa
zanubrutinib 80mg capsules

1. As per IQVIA dataset from April 2023 to March 2026
 2. As per IQVIA dataset for MAT March 2022 and MAT March 2026
 3. Across Top 15 companies in the IPM as per IQVIA
 4. As per IQVIA dataset for MAT March 2026
 5. As per IPSOS MAT December 2025 dataset – ranking among Indian companies

India: Initiatives Aimed at Supporting the Strong Base



Scale up the Oncology franchise anchored by innovative launches



Expand field-force across existing therapeutic areas to deepen market coverage



Launch differentiated products to drive growth in Chronic Respiratory & Cardiac



Drive turnaround momentum in the Diabetes franchise through GLIPIQ[®] launch




Expand OTC / DTC verticals to create an additional growth engine

Emerging Markets: Building Through Scale, Reach & Partnerships




Strong foundation through incremental expansions

Revenue (₹ million)



No dependence on a single market for growth¹



Large market opportunity



Strong current positioning with multiple tailwinds

Russia / CIS

>US\$20bn

- Strong Dermatology, Respiratory franchises
- Multiple leading brands commercialized: RYALTRIS®, ASCORIL™, CANDIBIOTIC™

LATAM

>US\$70bn

- Presence across large markets - Brazil, Mexico, Colombia
- Top-10 position in the Respiratory CVM of Brazil & Mexico²

MEA

>US\$20bn

- Regional market leader in Allergic Rhinitis with leading share in South Africa
- 2nd largest company in Kenya, 1st rank in CVM²


APAC

>US\$50bn

- Leader in Dermatology; 1st rank in CVM in the APAC² region
- Significant expansion of Respiratory portfolio

1. As of FY26
2. As per IQVIA MAT March 2026

Emerging Markets: Fastest Growing Market in the Next Five Years



Strengthen Oncology front-end capabilities in core markets to commercialize innovative portfolio



Expand field-force across Respiratory & Dermatology to gain additional share



Strengthen geographic reach through selectively expansion in additional high-potential countries




Focus on commercial execution of key brand launches to drive market share gains

Europe: Building a Higher-value Growth Platform




Leading growth region in the last five years

Revenue (₹ million)




Direct footprint in five major markets

- Glenmark presence
- 3rd party business



Increasing share of branded products



Successful expansion into Respiratory



Multiple additional products to be commercialized in the next 12-18 months

Europe: Scaling the Next Phase of Growth



Launch additional Respiratory products to gain leadership position in key markets



Strengthen RYALTRIS[®] position in key markets and drive market share gains



Successfully launch WINLEVI[®] and other companion products to strengthen the Dermatology franchise



Pursue in-licensing and M&A to strengthen overall market presence

North America: At an Inflection Point




 **Leading company in the region**

>86 million
total prescriptions¹


13th
rank in total prescriptions²

17th
rank in total volume²

Expansion across
Institutional & OTC

 **Well diversified portfolio**

Revenue contribution³



 **Leadership in commercialization**

#1
in 28% of the portfolio

#2
in 27% of the portfolio

#3
in 18% of the portfolio

>74%
top 3 in commercialized products⁴

 **Differentiated expansion**

Two generic **Respiratory** products commercialized

>20 **Injectable** products launched (via partnerships)

Selective addition of **OSD, Dermatology** products

In-house launch of **RYALTRIS®** via direct commercialization

1. As per IQVIA – Last 12 Months Ending March 2026
2. Among U.S. Generic Pharmaceutical Companies [includes Generics & Branded Generics]; Rx Only
3. Internal estimates as of FY26
4. Ranking based on Market Share using Extended Units for Preciseness; National Sales Perspective – March 2026

North America: Strengthening Core Areas to Support Growth



Continue launch momentum in Respiratory (2-3 launches in FY27e) and file additional 2-3 products every year



Scale Monroe injectables through increased filing & launch momentum; Continued investment for capacity expansion over the next 3-5 years



Build branded presence through RYALTRIS[®]; Evaluate Dermatology as the next branded growth platform



Expand presence in Institutional and OTC verticals over time



Continue scale-up of Canada business across all platforms

Winning in Three Global Therapy Areas

Nishan de Silva, M.D.

Global Strategy Advisor



Building Deep Expertise in Three Key Therapeutic Areas



Current Global Presence



Respiratory

- Ranked 3rd in India¹ and 3rd in Russia¹; among the leading companies in LATAM²
- Eight products launched across Europe; multiple other filings
- First generic launch of FloVent[®] 44mcg; multiple other generic product filings
- RYALTRIS[®] commercialized in 56 markets globally⁴



Dermatology

- Ranked 2nd in India¹ and 8th in Russia¹; among the leading companies in the APAC region²
- Growing OTC/DTC portfolio in select markets
- Leading player in US generics
- Expanding Specialty portfolio in Europe with WINLEVI[®] and HILKOTA[®]



Oncology

- Ranked among Top 5 Indian companies³
- Current presence across multiple Emerging Markets
- Successful launch of TEVIMBRA[®] & BRUKINSA[®] in India
- Building a commercial front-end to support Innovative Oncology launches



Future Strategy

Moving up the value chain through differentiated product launches

1. As per IQVIA MAT March 2026 dataset
2. As per IQVIA MAT March 2026 dataset
3. As per IPSOS MAT December 2025 dataset – ranking among Indian companies
4. As of April 2026

RYALTRIS®: From Vision to Global Leadership



>6mn

patients prescribed globally till date

>90

filings across the globe; 56 approvals received¹


>10

strategic partnerships with leading companies

US\$300mn

cumulative global sales as of FY26²

Global Sales Performance



Robust secondary sales growth in FY26



Recent launches: China, Thailand, Brazil (FY27e)



In-house launch in the USA


Key Commercial Partners



1. As of April 2026
2. Cumulative sales across all commercial markets between Glenmark and its partners since its first market launch


Innovative Brands Driving the Next Phase of Growth



	 Respiratory	 Dermatology		 Oncology				
	 Ryaltris [®] 665 mcg / 25 mcg (olopatadine hydrochloride and mometasone furoate monohydrate nasal spray)	 Winlevi (clascoterone) 10 mg/g cream	 Hilkota [™] cutaneous foam calcipotriol/betamethasone	 TEVIMBRA [®] (tiselimab-jsgf) Injection, for intravenous use (10 mg)	 Brukina [®] zanubrutinib tablets	Aumolertinib	 QINHAYO [™]	Trastuzumab Rezetecan
 Indication	Allergic Rhinitis	Acne Vulgaris	Plaque Psoriasis	NSCLC¹, CLL²	NSCLC	NSCLC, BTC, MSI-H tumours	HER2 tumours³	
 Key Regions	Global	Europe, South Africa	Global	India	India & Emerging Markets			
 Launch Timelines	Launched	Launched	FY27	Launched	FY27	FY28	FY29	
 Peak Sales	Estimated total annual global sales of US\$700-800 million over the next 7-8 years							

1. TEVIMBRA[®] is approved in 1L non-small cell lung cancer (NSCLC) in combination with Chemotherapy, in 2L NSCLC and in Oesophageal Squamous Cell Carcinoma (ESCC)
 2. BRUKINSA[®] is approved for five B-cell malignancies
 3. Trastuzumab Rezetecan is approved in China for HER2m NSCLC and under active clinical development for multiple other indications including HER2+ve breast cancer (BC) and HER2-low BC

Evolving Toward a Branded, Innovation-Led Portfolio



Differentiated launches to drive consistently high growth in branded markets

1. "Generics" include revenue from North America and rest of Europe that is not covered in Branded
2. "Branded" include all branded markets (India, Emerging Markets, parts of Europe) and branded products sold globally

Advancing Innovation in Next-Gen Biologics

Lida Pacaud, M.D.

President & Chief Executive Officer



Clinical-Stage Biotechnology Company at the Forefront of Innovation in Oncology



OUR MISSION

OUR VISION

“To provide curative therapies that extend and improve lives.”

“We dare to imagine a world where cure is possible.”



Innovative Biotech

- Core capabilities in biologics
- Global footprint: U.S., Switzerland and India



Biologics Discovery Engine

- Proprietary protein engineering platform (BEAT®)
- Next-generation multispecific antibodies which targets multiple tumour-associated antigens (TAAs) and acts as an immune cell activator



Robust Pipeline

- Clinical stage pipeline in Oncology
- Engaging different types of immune cells
- Three alliances

Multispecific™ Antibodies Will Drive the Next Wave of Innovation in Oncology



1990s

Tumor Lysis by ADCC
Cytotoxicity
Cancer Cell (Target)
Antibody
Fc Receptor
Effector Cell (NK cell & Monocyte)

TARGETED THERAPIES
FC Function-based
Tumor Killing

2010s

1 Release of Cancer cell antigens
2 Cancer antigen presentation
3 Priming and activation
4 Trafficking of T cells to tumors
5 Infiltration of T cells into tumors
6 Recognition cancer cells T cells
7 Killing of Cancer Cells

IMMUNO-ONCOLOGY
Checkpoint and Innate
Immunity Modulators

2014

Tumor cell
CD38
High Affinity
Low-Mid Affinity
TCR/CD3
T Cell

BISPECIFIC ANTIBODIES
CD3 T-cell engagers

2017

Autologous
Cell therapy

Patient

CAR-T CELLS
Engineered T cells

Next Wave

MULTISPECIFICS™

Targeting multiple cell surface antigens simultaneously on cancer and immune cells to drive potent anti-tumor immune responses

Diversity of Immune Cell Engagement Across Hematologic & Solid Tumour Indications, and Autoimmune Diseases



ONCOLOGY ASSET	DESCRIPTION	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	RIGHTS
ISB 2001 (ABBV-2001)	CD38 x BCMA x CD3 Trispecific T-cell engager	Multiple Myeloma	[Green arrow]					 <small>A new way for a new world</small>
ISB 2301	Multispecific immune cell activator	Solid Tumours	[Green arrow]					
ISB 2302	Bispecific immune modulator	Hematologic & Solid Tumours	[Green arrow]					
ISB 2501	Trispecific T-cell engager	Solid Tumours	[Green arrow]					

*IGI will partner with Glenmark to develop, manufacture, and commercialize ISB 2001 in all territories outside AbbVie's licensed markets

IMMUNOLOGY ASSET	DESCRIPTION	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	RIGHTS	
ISB 880 (LAD191)	IL-1RAP antagonist mAb	Hidradenitis Suppurativa	[Light blue arrow]						
Telazolimab (ISB 830)	OX40 antagonist mAb	Atopic Dermatitis	[Light blue arrow]						
ISB 830-X8 (STAR-0310)			[Light blue arrow]						




ISB 2001 / ABBV-2001

Trispecific T- cell Engager in Multiple Myeloma Targeting CD38 x BCMA x CD3

Ph1 TRIgnite-1 Study Progressing Rapidly with The Goal to Determine RP2D by 4Q 2026

- To date, **>145 subjects have been dosed** in the TRIgnite-1 Phase 1 study (**42** in dose escalation and **>100** in dose expansion).
- **Safety and efficacy data from all subjects continue to be promising** and are consistent with the data previously presented at **ASCO 2025**
- A Phase 1/2 multi cohort combination study in Multiple Myeloma with other antimyeloma therapies is planned to initiate in Q3 2026

ISB 2301: a First-in-Class Multispecific™ Immune Cell Activator Targeting Solid Tumors



- Next-generation multispecific antibody **targets three tumour-associated antigens (TAAs)**, activating both **T cells** and **natural killer (NK) cells**
- IGI's clinically validated **BEAT® platform** enabled the development of ISB 2301
- **Penta-specific** antibody-like immune therapeutic based on BEAT® platform for the treatment of several solid tumor indications
- Targeting three tumor specific antigens to counteract TAA downregulation escape mechanisms
- T cell activation by checkpoint inhibition (CPI) activities
- Dual antibody dependent cell cytotoxicity (ADCC)
- Supports anti-tumor type 1 immune response
- Excellent preliminary PK and tolerability in non-human primates
- **Rapidly advancing toward the clinic; IGI intends to submit an IND application later this year**

IGI well poised to remain self-sustaining going forward



Strategic Revenue Streams

Diversified income over the next few years through:

- Development and regulatory milestones payments expected from partnered portfolio
- New licensing partnerships to be concluded on the pipeline
- Sale milestone payments and tiered royalties upon successful commercialization
- Successful completion of IPO

Investment Outlook

Focused capital allocation:

- ISB 2301 IND filing to be completed by end-CY26
- Two additional discovery programs in Oncology to progress forward
- Targeting 1 IND filing every year
- Average annual investment to remain ~US\$70 million

Creating Long-term Shareholder Value

Anurag Mantri

Executive Director & Global Chief Financial Officer



Delivering on Strategic & Financial Commitments



Criteria	Investor Day 2022 Guidance	Achievement	
 Revenue	10-12% growth over next 3-4 years		~12% CAGR between FY22-FY26
 Branded Business Contribution	~2/3rd of consolidated revenue to be contributed by branded markets	On track	>60% revenue from branded markets
 Innovation Portfolio Launch	Commercial launch of 1 innovative asset		Innovative Oncology: TEVIMBRA [®] , BRUKINSA [®] Specialty Dermatology: WINLEVI [®]
 EBITDA Margin	23% by FY27	On track	21-22% guidance for FY27e
 ROCE	23% by FY27		>23% in FY27e
 IGI Funding	Ensure IGI is self-funded		ISB 2001 licensing deal with AbbVie
 Net Debt	Zero net debt by FY26		Zero gross debt as of FY26

Well Positioned for a Changing Macro Environment



Key Risks & Business Impact



Growth Slowdown in Markets



- Drag on overall top-line growth
- Negative impact on operating margins



Evolving Global Geopolitics



- Supply chain disruptions
- Higher distribution costs



Macro-economic Challenges



- High inflation / interest rates
- Currency volatility

Ongoing Mitigations



- Increased scale in existing branded markets
- Higher contribution of innovative products



- Transitioning to portfolio with higher gross margin contribution
- Continuous optimization of working capital investments




- Natural currency hedge via well diversified business model
- Strengthened overall balance sheet with superior return ratios

Structural Margin Improvement Through Portfolio Enhancement & Operating Leverage



EBITDA Margin Trajectory



Key Drivers

- 1 Increased contribution from Branded Portfolio**
Higher branded contribution → structurally better gross margins
- 2 Broad-based Growth Expansion in Key Regions**
Incremental investments for long-term leadership
- 3 Differentiated Generic Launches**
Respiratory and Injectable products with select FTFs to drive US business
- 4 IGI Self-sufficiency**
Validation of IGI platform improves strategic revenue stream


Investing in growth while moving up the margin trajectory through product mix, business scale & R&D discipline

Stronger Balance Sheet Creating Financial Flexibility



Net Debt Trajectory

₹ million




Current Ratings:

- S&P: BB+ (stable)
- Crisil: AA (positive)
- India Ratings: IND AA (positive)

Return on Investment Profile

Return on Capital Employed (ROCE)²

Return on Equity (ROE)³



Balance sheet fortification → stronger return profile and financial flexibility

1. Based on consensus estimates for FY27 of select listed pharmaceutical companies with a similar business model and geographical presence

2. FY27e ROCE = EBIT / Capital Employed; Capital Employed = Average debt + Average shareholder's equity

3. FY27e ROE = Net profit / Average shareholder's equity

Well Defined Path to Deliver Substantial Shareholder Value



Driver

Medium-term Outlook



Growth



- **Broad-based growth with greater contribution from branded markets**
- **Revenue Growth: 13-15% CAGR**



Profitability



- **Growth initiatives with shorter payback periods and superior returns**
- **Target ~1% margin improvement in FY28 through operating leverage**



Investments



- **Working capital to be structurally below industry average**
- **ROCE-gated selective CAPEX and M&A to support long-term growth**



Return Ratios



- **Continuously target >23% ROCE and >20% ROE**
- **Maintain net cash position post all strategic actions**

Thank You

Investor Day 2026

Tuesday, 9 June 2026

Q&A Session

Investor Day 2026

Tuesday, 9 June 2026

Appendix



Abbreviation	Full Form	Abbreviation	Full Form
AD	Atopic Dermatitis	ICANS	Immune effector Cell-Associated Neurotoxicity Syndrome
ADC	Antibody-Drug Conjugate	IGI	Ichnos Glenmark Innovation
APAC	Asia-Pacific	IPM	Indian Pharmaceutical Market
BEAT	Bispecific Engagement by Antibodies based on the T cell receptor	IPO	Initial Public Offering
BTC	Biliary Tract Cancer	LATAM	Latin America
CAGR	Compound Annual Growth Rate	M&A	Mergers & Acquisitions
CAPEX	Capital Expenditure	MEA	Middle East & Africa
CEE	Central & Eastern Europe	MSI-H	High Microsatellite Instability
CIS	Commonwealth of Independent States	MRD	Minimal Residual Disease
CLL	Chronic Lymphocytic Leukemia	NBE	New Biological Entity
CR/sCR	Complete Response/stringent Complete Response	NCE	New Chemical Entity
CRS	Cytokine Release Syndrome	NME	New Molecular Entity
CT	Clinical Trial	ORR	Overall Response Rate
CY	Calendar Year	OTC	Over-The-Counter
DOR	Duration of Response	pMDI	Pressurized Metered Dose Inhaler
DPI	Dry Powdered Inhaler	RP2D	Recommended Phase 2 Dose
DTC	Direct-To-Consumer	R&D	Research & Development
EBIT	Earnings Before Interest & Tax	ROCE	Return On Capital Employed
EBITDA	Earnings Before Interest, Tax, Depreciation, Amortization	ROE	Return On Equity
EM	Emerging Markets	TA	Therapeutic Area
EU	Europe	TCE	T-cell Engager
FTF	First-to-File	TREAT	Trispecific Engagement by Antibodies based on the T cell receptor
FY	Fiscal Year	UK	United Kingdom
Gx	Generics	US, USA	United States of America
HS	Hidradenitis Suppurativa	VGPR	Very Good Partial Response
HV	Healthy Volunteers	WEU	Western Europe

All brand names and trademarks are the property of their respective owners

RYALTRIS®: Glenmark Pharmaceuticals Ltd.; JABRYUS®: Pfizer Inc, USA; Pfizer India; WINLEVI®: Cassiopea, S.p.A.; TEVIMBRA®, BRUKINSA®: BeOne Medicines; QiNHAYO™: Glenmark Pharmaceuticals Ltd. FloVent®: GSK or licensor